Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Fasching

Showing results (71-80 of 109) with videos related to

Pageof 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2021
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trialA Llop-Guevara, S Loibl, G Villacampa, et al.
British Journal of Cancer|August 16, 2012
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trialI Witzel, S Loibl, G von Minckwitz, et al.
Breast Cancer Research : BCR|August 31, 2023
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrantP Neven, P A Fasching, S Chia, et al.
Geburtshilfe Und Frauenheilkunde|September 27, 2014
Percent Mammographic Density and Dense Area as Risk Factors for Breast CancerC Rauh, C C Hack, L Häberle, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2016
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)G von Minckwitz, M Rezai, H Tesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosisM Untch, G von Minckwitz, G E Konecny, et al.
Geburtshilfe Und Frauenheilkunde|August 1, 2017
Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A StudyA Hein, B Rack, L Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapyJ L Lindner, S Loibl, C Denkert, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Hormone Therapy and its Effect on the Prognosis in Breast Cancer PatientsC Rauh, F Schuetz, B Rack, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgeryM Untch, P A Fasching, G E Konecny, et al.
Pageof 11

Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2021
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trialA Llop-Guevara, S Loibl, G Villacampa, et al.
British Journal of Cancer|August 16, 2012
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trialI Witzel, S Loibl, G von Minckwitz, et al.
Breast Cancer Research : BCR|August 31, 2023
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrantP Neven, P A Fasching, S Chia, et al.
Geburtshilfe Und Frauenheilkunde|September 27, 2014
Percent Mammographic Density and Dense Area as Risk Factors for Breast CancerC Rauh, C C Hack, L Häberle, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2016
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)G von Minckwitz, M Rezai, H Tesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosisM Untch, G von Minckwitz, G E Konecny, et al.
Geburtshilfe Und Frauenheilkunde|August 1, 2017
Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A StudyA Hein, B Rack, L Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapyJ L Lindner, S Loibl, C Denkert, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Hormone Therapy and its Effect on the Prognosis in Breast Cancer PatientsC Rauh, F Schuetz, B Rack, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgeryM Untch, P A Fasching, G E Konecny, et al.
Pageof 11